Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Arcus Biosciences, Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Toray Industries, Inc